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Abstract (247 words) 
Objective: Several questionnaires have been developed to screen for psoriatic arthritis (PsA) 
but head to head studies have found limitations.  This study aimed to develop new 
questionnaires encompassing the most discriminative questions from existing instruments. 
 
Methods: Data from the CONTEST study, a head to head comparison of three existing 
questionnaires, were used to identify items with a Youden’s index of ≥0.1.  These were 
combined using four approaches: CONTEST- simple additions of questions; CONTESTw- 
weighting using logistic regression; CONTESTjt- addition of a joint manikin and 
CONTESTtree- additional questions identified by CART analysis.  These candidate 
questionnaires were tested in independent datasets. 
 
Results: 12 individual questions with a Youden’s index of ≥0.1 were identified but 4 of these 
were excluded due to duplication and redundancy.  Weighting for two of these questions, 
was included in CONTESTw.  Receiver operating characteristic (ROC) curve analysis showed 
that involvement in six joint areas on the manikin was predictive of PsA for inclusion in 
CONTESTjt.  CART analysis identified a further 5 questions for inclusion in CONTESTtree.  
CONTESTtree was not significant on ROC analysis and discarded.  The other three were 
significant in all datasets, although CONTESTw was slightly inferior to the others in the 
validation datasets.  Potential cut points for referral are discussed. 
 
Conclusion: Of four candidate questionnaires combining existing discriminatory items to 
identify psoriatic arthritis in people with psoriasis  three were found to be significant on ROC 
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analysis.  Testing in independent datasets identifies two questionnaires: CONTEST and 
CONTESTjt that should be pursued for further prospective testing.   
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Significance and Innovations 
 Existing screening questionnaires for PsA have limitations and head-to-head 
studies show that they identify different cases of PsA.  The new candidate 
questionnaires in this paper combine the most discriminatory items from existing 
questionnaires to attempt to create a new, optimal, questionnaire. 
 Two candidate questionnaires (CONTEST and CONTESTjt) performed well in 
both development and validation cohorts.  These require further prospective testing 
to allow recommendation of the best performing tool.  
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Psoriatic arthritis is a form of inflammatory arthritis associated with skin psoriasis.  In the 
majority of cases, patients present with skin psoriasis prior to developing symptoms of 
arthritis(1).  There is evidence that a significant proportion of psoriasis patients in 
dermatology clinics(2) and primary care(3) also have unidentified psoriatic arthritis.  A 
variety of screening questionnaires have been developed in an attempt to aid identification 
of psoriasis patients with possible PsA for subsequent referral.  These are typically paper-
based questionnaires that are completed by the patients and have a cut-off above which 
referral is suggested.  Most of the questionnaires developed (PAQ(4), PASE(5), PEST(3), 
ToPAS(6)) have been validated in a variety of independent populations but not compared 
directly.  Recently, the CONTEST study compared three popular screening questionnaires 
(PASE, PEST and ToPAS) head-to-head in secondary care dermatology clinics at ten sites in 
the UK(7).  The sensitivities and specificities of all three questionnaires were lower than 
previously found with slightly disappointing AUCs of around 0.6.  Interestingly, the 
prevalence of PsA increased according to the number of positive instruments: the 
prevalence was 19.1%, 34.0% and 46.8% with one positive, two positive and three positive 
scores respectively(7).  This suggests that a combination of the best performing items from 
each of the questionnaires may have higher sensitivity and specificity than the individual 
instruments.  The aim of this analysis was to investigate which individual questions from 
each of the questionnaires performed well and whether a combination of these questions 
could improve the sensitivity and specificity in identifying PsA. 
Methods 
Development Cohort (CONTEST) 
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In the CONTEST study(7), patients with psoriasis but without a diagnosis of PsA were 
recruited from 10 sites in the UK.  Local collaborating dermatologists invited consecutive 
patients with psoriasis attending dermatology hospital clinics to participate. Patients were 
excluded if they had an established diagnosis of PsA. Each patient was given an envelope 
which included a cover letter, study information sheet, the three screening questionnaires 
(in a random order) and a return envelope. All current versions of the screening 
questionnaires were used in the study including the updated version 2 of the ToPAS.  
Those who scored positively on any of the 3 screening forms were contacted by the local 
study team and invited to attend for further evaluation by a rheumatologist. Those scoring 
negative on all three screening forms took no further part in the study. Missing data were 
not interpolated – only questions answered were scored for the purpose of recording a 
positive response.  Patients were classified as having PsA using the CASPAR criteria. 
A total of 938 patients were given the questionnaires and 657 returned them. Of these, 318 
were positive for at least one of the questionnaires and were invited to attend for an 
examination. Of these, 195 attended. There were 47 cases of PsA according to the CASPAR 
criteria and in addition, 8 cases  not fulfilling CASPAR criteria (mostly because a test for 
rheumatoid factor was not available) but were felt to have a diagnosis of PsA by the 
examining rheumatologist. 
Validation Cohorts 
Data from two comparative independent head-to-head studies based in Dublin and Utah 
were used to test the new proposed questionnaires (2, 8). Both of these studies evaluated 
some patients with known PsA and some with psoriasis and no known diagnosis of 
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inflammatory arthritis.  Since the latter are the target audience for screening 
questionnaires, only these cohorts were evaluated.  The Dublin data included 100 
consecutive psoriasis patients attending dermatology clinics with no known diagnosis of 
inflammatory arthritis.  They completed all three of the questionnaires but no data were 
available for the joint mannequin.  All patients were examined to assess for PsA. A total of 
29 patients were diagnosed with PsA according to the CASPAR criteria.  In Utah, recruitment 
letters were mailed to all patients enrolled in the Utah Psoriasis Initiative registry and 
interested participants attended for a study visit.  Additionally, patients with psoriasis 
attending for routine dermatology or rheumatology appointments were also invited to 
participate.  The Utah data included 269 patients who had completed all three 
questionnaires and been examined to assess for PsA.  Of these, 124 had an established 
diagnosis of PsA leaving a subset of 145 patients with no previous diagnosis of inflammatory 
arthritis who were included in this analysis.  A total of 80 patients were found to have 
previously undiagnosed PsA. 
 Statistical Methods for analysis 
Various methods were pursued to develop a new screening questionnaire based on the 
most discriminatory questions within the three existing questionnaires.  For development of 
the new candidate questionnaires, the diagnosis based on the CASPAR criteria was used to 
ensure uniformity across centres and cohorts.  The questions used to calculate scores for 
the PEST and ToPAS questionnaires are dichotomous questions, however the questions in 
the PASE questionnaire use a Likert scale of 1 (strongly disagree) to 5 (strongly agree).  In 
order to compare the questions directly, the PASE questions were transformed into a 
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dichotomous variable using scores of 1-3 (strongly disagree, disagree or no opinion) as 
negative but scores of 4 (agree) and 5 (strongly agree) as positive.   
All questions from the PASE, ToPAS and PEST questionnaire were investigated individually to 
look at their sensitivity, specificity and Youden’s index and significance using the Chi-
squared test.  Youden’s index (J=sensitivity + specificity – 1) was used as a simple summary 
measure of misclassification error for the individual items in the questionnaires.  This test 
performs well in such cohorts with low disease incidence and is a useful assessment of both 
sensitivity and specificity of a diagnostic test.  The maximal Youden’s index for the individual 
items was 0.19, so a pragmatic cut off point of 0.1 was used to identify candidate questions.  
 
Method 1: All questions with a Youden’s index of ≥0.1 were considered for inclusion in a 
new questionnaire (CONTEST).  As the questions originate from independent 
questionnaires, it is likely that some questions will ask about the same features (e.g. nail 
disease or dactylitis) leading to some repetition.  To minimise overlap in these situations, 
the question with the highest discrimination was included.   
Method 2: The same methodology was used as per Method 1, except logistic regression was 
subsequently used to identify any individual questions that were independently predictive 
of arthritis; odds ratios (OR) from the regression were used for weighting of these questions 
within the complete questionnaire (CONTESTw).   
Method 3: In addition to the standard dichotomous or Likert-scale questions included in the 
questionnaires, the PEST questionnaire also contains a joint mannequin where patients are 
asked to tick “joints that have caused you discomfort”.  ROC analysis was used to identify 
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whether the number of joints ticked was predictive of PsA and what cut off had the greatest 
sensitivity and specificity to predict PsA.  This was then dichotomised to a score of 0 if less 
than the cut off were ticked and 1 if that number or more joints were causing discomfort.  
This question was then added to the questions identified in method 1 (CONTESTjt). 
Method 4: All of the individual questions were entered into a classification and regression 
tree (CART) analysis to develop a classification tree to identify PsA.  The CART method 
selects independent variables that differentiate arthritis but allows different combinations 
of predictor variables in different subgroups creating a flexible classification system.  For 
example, this potentially allows different questions to be identified for patients with and 
without enthesitis symptoms.  This analysis was used to identify additional questions that 
could be added to those already identified in method 1 to assess whether they improved 
differentiation (CONTESTtree). 
Comparison of Proposed Questionnaires 
All of the questionnaires identified above using methods 1-4 were then assessed using ROC 
analysis using diagnosis of PsA by CASPAR criteria as the state variable.  AUCs were used to 
compare the proposed questionnaires with each other and also with the original 
questionnaires from which these were derived. The ROC curves were then used to identify 
cut points for positivity that could be used to screen for PsA. 
Results 
Method 1 (CONTEST) 
Sensitivities and specificities for all of the questions contained in the PEST, PASE and ToPAS 
questionnaires are shown in table 1.  Using regression analysis, each question was examined 
12 
 
to see if individual questions predicted the likelihood of PsA.  In this individual analysis, only 
2 questions showed significant differentiation of PsA cases using Fishers exact test: ToPAS 
2A “Have you ever noticed any of these changes in your fingernails – pits in the nails?” and 
PEST 4 “Have you had pain in your heel?”.  These two questions and a further 10 questions 
had a Youden score of ≥0.1 and these were considered for inclusion into the first candidate 
questionnaire (shown in table 2). 
There were two questions related to nail pitting (PEST 3 and ToPAS 2A) and as ToPAS 2A 
performed best, PEST 3 was excluded from further analysis.  ToPAS 7A was excluded from 
subsequent analysis; there appeared to be confusion regarding this question as it was not 
answered by the majority of patients.  ToPAS 9 and 9B were excluded as they ask 
predominantly about a skin rash, but our proposal for this new questionnaire was that it 
would be used in patients with established psoriasis.  The joint symptoms mentioned in 
these questions are covered by other questions already included.  This left a total of eight 
questions to form the CONTEST questionnaire with a score of 0-8. 
Method 2 (CONTESTw) 
Logistic regression (forward stepwise) was used to identify independent predictors of PsA 
which identified two questions with significant chi-squared results: ToPAS 2A “Have you 
ever noticed any of these changes in your fingernails – pits in the nails?” and PEST 4 “Have 
you had pain in your heel?”.  For ToPAS 2A, the OR was 4.92 (95% CI 1.42, 17.03; p=0.012) 
and for PEST 4, the OR was 2.23 (95% CI 1.08, 4.61; p=0.031).  These odds ratios were 
applied to the relevant questions to create a weighted version of the 8 item CONTEST 
questionnaire where ToPAS 2A was weighted as 5, PEST 4 was weighted as 2 and all of the 
other questions were weighted as 1.  Therefore the CONTESTw has a score of 0-13.  
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Method 3 (CONTESTjt) 
ROC analysis identified that the number of positive joints selected on the PEST mannequin 
alone was predictive of PsA with a AUC of 0.63 (95% CI 0.54, 0.72; p=0.009).  Given the 
proposed use of the questionnaire as a screening tool, a slightly higher sensitivity than 
specificity was sought.  An optimal cut-off of 6 joints or more (sensitivity 0.8, specificity 
0.39) was chosen and added to CONTEST as a dichotomised positive/negative score, thus 
creating the CONTESTjt questionnaire (scoring 0-9). 
Method 4 (CONTESTtree) 
The CART analysis identified 8 questions and developed a five level tree with 10 terminal 
nodes.  The structure of the classification tree and the prevalence of PsA at each of the 
terminal nodes are shown in figure 1.  As expected, there was some overlap with the 
questions selected for the CONTEST and CONTESTw questionnaire, although new questions 
were also included.  The first variable selected by the CART analysis was PEST 4 relating to 
heel pain, which was identified previously as a significant discriminator in both the logistic 
regression and the individual sensitivity and specificity analysis.  Interestingly ToPAS 2A 
relating to nail pitting was not included in the classification tree.   The classification tree 
included ToPAS 7 and PASE 4 that are already included in the CONTEST questionnaire, but 
also identified ToPAS questions 6, 7B, 8, 8A and 8B in subsequent nodes.  These additional 
five questions were added to the original 8 CONTEST questions to create the CONTESTtree 
questionnaire, giving a total score of 0-13. 
Comparison of Proposed Questionnaires 
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All of the questionnaires identified above (CONTEST, CONTESTw, CONTESTjt and 
CONTESTtree) were then assessed using ROC analysis in the original CONTEST-UK cohort to 
assess their prediction of PsA (table 3).  All of the questionnaires except that derived from 
the CART analysis reached significance and showed higher AUC than those found in the 
same data for the original PASE, PEST and ToPAS questionnaires in the development cohort.  
Given that CONTESTtree did not show a significant AUC, this was not pursued further.  ROC 
analysis in the Dublin and Utah cohort confirmed similar AUC results, although the weighted 
questionnaire (CONTEST-w) performed slightly inferiorly than the standard questionnaires in 
these independent cohorts.   
Co-ordinates of the ROC curves for the other three questionnaires (CONTEST, CONTEST-w 
and CONTEST-jt) were then examined using the three cohorts (CONTEST-UK, Dublin and 
Utah) to assess optimal cut-points for the different candidate questionnaires (table 4).  
Given that these questionnaires are screening tools, when assessing cut points, the balance 
of sensitivity and specificity should be in favour of higher sensitivity.  Interestingly the 
optimal cut-points for these candidate questionnaires differed in the three cohorts with 
higher cut-points appearing optimal in the UK data when compared to both the Dublin and 
Utah cohorts.  Taking into account the results in all of the cohorts, provisional cut offs for 
the questionnaires are suggested as follows: CONTEST – 4, CONTESTw – 8 and CONTESTjt – 
5.  However as can be seen in table 4, the optimal cut offs vary in the different cohorts and 
further validation work is necessary before finalising the cut-offs. 
Discussion 
The aim of this study was to use all three questionnaires to identify the most helpful 
questions from each of the instruments and combine them into a new tool.  Different 
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statistical approaches were used both to identify key questions and combine them into new 
tools.  Three of the four proposed questionnaires reached significance in ROC curve testing 
with higher AUC in the CONTEST data than seen with the original questionnaires.  These 
findings are not altogether surprising as instruments are bound to perform best in the 
dataset in which they are developed.  Further retrospective validation in independent 
datasets has shown that the weighted questionnaire (CONTESTw) performs less well than 
CONTEST and CONTESTjt, both of which show reasonable performance in these datasets.   
Many screening tools to identify PsA have been developed by independent groups of 
researchers in recent years.  Most have undergone validation, but until recently there has 
been little research directly comparing questionnaires with the aim of identifying one 
questionnaire that can be recommended for routine clinical use in the future.  There have 
been three head-to-head comparisons that have shown conflicting results but have all 
identified problems in identifying PsA(2, 7, 8).  In the CONTEST study, the questionnaires 
identified many cases who had musculoskeletal symptoms due to an alternative diagnosis 
particularly osteoarthritis or degenerative disease leading to poor specificity(7).  In the 
Dublin study, the specificity was high, but many cases of PsA with predominant axial disease 
or entheseal disease remained unidentified(2).  In the Utah study, both sensitivity and 
specificity were lower than hoped and the instruments were notably less sensitive in cases 
with recent onset mild disease(8).  All of these studies tested the questionnaires in patients 
with skin psoriasis but no known inflammatory arthritis, but only positive responders on one 
or more questionnaire were examined in the UK CONTEST study, whereas all patients were 
assessed for PsA in the Dublin and Utah cohorts.  This key difference in study design results 
in a slight overestimate of sensitivity and underestimate of specificity in the CONTEST 
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cohort.  This is a limitation for the development of the CONTEST questionnaires as patients 
who were negative on all three screening questionnaires were not evaluated and therefore 
their data is not included in these analyses.  Although this methodology may have missed 
some people with PsA, it is likely that their symptoms would be minimal if they are not 
identified by the questionnaires. 
Further prospective validation is now required to identify the optimal questionnaire for PsA 
screening in both primary and secondary care.  The existing studies have already highlighted 
that the same questionnaires can have conflicting results dependent on the population 
studied and methodology used.  The performance of all questionnaires should ideally be 
carefully tested in different subsets, including patients with psoriasis recruited from primary 
care (who should be more representative of the general population) and those recruited 
from dermatology clinics who are more likely to have severe skin disease. 
In summary, this analysis attempts to identify the most discriminatory questions from any of 
the studied questionnaires, and to combine these into new candidate questionnaires for 
further validation.  The initial evidence from this analysis has created three candidates with 
marked improvements in AUC compared to the PASE, PEST and ToPAS questionnaires.  If 
replicated in future analyses, any one of the CONTEST questionnaires outlined above could 
be recommended for future clinical use. 
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Table 1 – Sensitivities and specificities of all individual questions in predicting PsA cases 
Question Sensitivity Specificity Youdens Chi-squared significant 
PEST1 0.83 0.25 0.08 1.33 ns 
PEST2 0.42 0.61 0.03 0.17 ns 
PEST3 0.77 0.33 0.10 1.52 ns 
PEST4 0.66 0.53 0.19 4.97 0.03 
PEST5 0.60 0.51 0.11 1.70 ns 
PASE1 0.68 0.40 0.08 0.87 ns 
PASE2 0.81 0.27 0.08 1.27 ns 
PASE3 0.65 0.46 0.11 1.83 ns 
PASE4 0.57 0.58 0.15 2.84 ns 
PASE5 0.47 0.64 0.11 1.63 ns 
PASE6 0.34 0.70 0.04 0.25 ns 
PASE7 0.57 0.52 0.09 1.19 ns 
ToPAS 1 0.97 0.05 0.02 0.09 ns 
ToPAS 2A 0.89 0.27 0.16 5.31 0.02 
ToPAS 2B 0.71 0.44 0.15 2.87 ns 
ToPAS 2D 0.80 0.26 0.06 0.58 ns 
ToPAS 3 0.98 0 -0.02 3.25 ns 
ToPAS 4 0.96 0 -0.04 6.53 0.01 
ToPAS 5 0.96 0.07 0.03 0.49 ns 
ToPAS 5B 0.91 0.17 0.08 1.56 ns 
ToPAS 6 0.39 0.68 0.07 0.75 ns 
20 
 
ToPAS 7 0.50 0.65 0.15 3.42 ns 
ToPAS 7A 0.69 0.41 0.10 0.92 ns 
ToPAS 7B 0.43 0.56 -0.01 0.03 ns 
ToPAS 8 0.57 0.48 0.05 0.32 ns 
ToPAS 8A 0.66 0.24 -0.10 1.49 ns 
ToPAS 8B 0.68 0.32 0 0 ns 
ToPAS 9 0.89 0.22 0.11 2.79 ns 
ToPAS 9B 0.89 0.23 0.12 2.66 ns 
ToPAS 10 0.80 0.25 0.05 0.48 ns 
ToPAS 12 0.15 0.91 0.06 1.27 ns 
 
Key – grey shading indicates Youden’s index ≥0.1, dark grey indicates inclusion in 
questionnaire 
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Table 2 – All individual questions with Youden’s score of ≥0.1 
QUESTION 
NUMBER 
ORIGIN WORDING Included in 
CONTEST 
questionnaire 
PEST 3 PEST Do your finger nails or toe nails have holes or pits? NO 
PEST 4 PEST Have you had pain in your heel? YES 
PEST 5 PEST Have you had a finger or toe that was completely 
swollen and painful for no apparent reason? 
YES 
PASE 3 PASE My back hurts. YES 
PASE 4 PASE My joints become swollen. YES 
PASE 5 PASE My joints feel “hot”. YES 
ToPAS 2A ToPAS  Have you ever noticed any of these changes in 
your fingernails: Pits in the nails as shown in figure 
1. 
YES 
ToPAS 2B ToPAS  Have you ever noticed any of these changes in 
your fingernails: Lifting of the nail from the nail 
bed as shown in figure 2. 
YES 
ToPAS 7 ToPAS  Have you ever had neck pain lasting at least 3 
months that was not injury related? 
YES 
ToPAS 7A ToPAS Was the neck pain accompanied by stiffness? NO 
ToPAS 9 ToPAS Have you ever had a skin rash on any part of your 
body at the same time as joint pain, joint-stiffness 
or swollen red joints? 
NO 
22 
 
ToPAS 9B ToPAS Do you have skin rash on any part of your body at 
the same time as joint pain, joint-stiffness or 
swollen red joints now? 
NO 
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Table 3 – Receiver operator characteristic (ROC) curve analysis of existing and proposed 
questionnaires in the CONTEST dataset. 
Questionnaire AUC Lower CI Upper CI P value 
CONTEST 0.69 0.57 0.81 0.01 
CONTESTw 0.74 0.63 0.85 0.001 
CONTESTjt 0.70 0.58 0.82 0.006 
CONTESTtree 0.59 0.46 0.73 0.20 
PEST 0.61 0.52 0.70 0.02 
PASE 0.59 0.51 0.68 0.05 
ToPAS 0.55 0.46 0.65 0.27 
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Table 4 – Sensitivities and specificities of all cut offs for the proposed questionnaires in the 
development (UK) and two validation cohorts (Dublin and Utah) 
 UK- CONTEST 
(n=195) 
Dublin 
(n=100) 
Utah 
(n=145) 
Questionnaire Cut 
point 
Sens Spec Sens Spec Sens Spec 
PEST 3 0.766 0.32 0.275 0.98 0.708 0.523 
PASE 44 0.745 0.385 0.24 0.94 0.692 0.477 
PASE 47     0.585 0.568 
TOPAS 8 0.766 0.297 0.41 0.90 0.662 0.386 
CONTEST 2 1 0.015 .897 0.324 0.923 0.136 
 3 1 0.154 .793 0.789 0.800 0.386 
 4 0.86 0.354 .379 0.887 0.615 0.659 
 5 0.82 0.523 .207 0.986 0.446 0.818 
 6 0.50 0.723 .069 0.986 0.246 0.886 
 7 0.27 0.846 .000 0.986 0.123 0.955 
 8 0.14 0.938 .000 1.0 0.092 0.955 
CONTEST-w 3 1 0.015 .828 0.324 0.877 0.227 
 4 1 0.123 .759 0.338 0.785 0.295 
 5 1 0.154 .724 0.338 0.723 0.364 
 6 1 0.231 .690 0.380 0.677 0.409 
 7 0.96 0.323 .655 0.789 0.615 0.5 
 8 0.86 0.477 .448 0.887 0.523 0.659 
25 
 
 9 0.82 0.538 .310 0.944 0.400 0.773 
 10 0.77 0.662 .069 0.986 0.277 0.909 
 11 0.36 0.815 .034 0.986 0.185 0.932 
 12 0.27 0.892 .000 0.986 0.123 0.955 
CONTEST-jt 3 1 0.108 n/a n/a 0.862 0.205 
 4 0.96 0.246 n/a n/a 0.754 0.500 
 5 0.86 0.369 n/a n/a 0.569 0.705 
 6 0.82 0.615 n/a n/a 0.400 0.818 
 7 0.46 0.723 n/a n/a 0.246 0.886 
 8 0.27 0.846 n/a n/a 0.123 0.955 
 9 0.14 0.938 n/a n/a 0.077 0.955 
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Figure 1 – Classification and regression tree (CART) analysis to identify PsA cases 
 
 
 
 
 
